Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

November 19, 2018

Study Completion Date

February 1, 2019

Conditions
Prostatic Neoplasms
Interventions
DRUG

Leuprolide Mesylate

Subcutaneous injection of 25mg Leuprolide Mesylate

Trial Locations (21)

10408

National Cancer Center, Gyeonggi-do

13620

Seoul National University Bundang Hosptal, Gyeonggi-do

14068

Hallym University Sacred Heart Hospital, Gyeonggi-do

23462

Urology of Virginia, PLLC, Virginia Beach

28025

Carolina Clinical Trials, LLC, Concord

35209

Urology Centers of Alabama, Homewood

41931

Keimyung University Dongsan Medical Center, Daegu

49241

Pusan National University Hospital, Busan

50009

Hospital of Lithuanian University of Health Sciences Kauno klinikos, Kaunas

78229

Urology San Antonio, P.A, San Antonio

80211

The Urology Center of Colorado, Denver

85704

Arizona Institute of Urology, Tucson

92288

Klaipėda University Hospital, Klaipėda

500 05

Fakultní nemocnice Hradec Králové, Urologická klinika, Hradec Králové

779 00

Uromedical Center Olomouc, Olomouc

140 59

Thomayerova nemocnice, Urologické oddělení, Prague

08660

National Cancer Institute, Vilnius

08661

Vilnius University Hospital, Santaros klinikos, Vilnius

080 01

UROCENTRUM MILAB, s.r.o., Prešov

012 07

Fakultná nemocnica s poliklinikou Žilina Urológia, Žilina

02841

Korea University Anam Hospital, Seoul

All Listed Sponsors
lead

Foresee Pharmaceuticals Co., Ltd.

INDUSTRY